GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mereo BioPharma Group PLC (NAS:MREO) » Definitions » Accumulated other comprehensive income (loss)

Mereo BioPharma Group (Mereo BioPharma Group) Accumulated other comprehensive income (loss) : $-17.49 Mil (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Mereo BioPharma Group Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. Mereo BioPharma Group's Accumulated other comprehensive income (loss) for the quarter that ended in Dec. 2023 was $-17.49 Mil.

Mereo BioPharma Group's quarterly Accumulated other comprehensive income (loss) increased from Dec. 2022 ($-21.69 Mil) to Jun. 2023 ($178.76 Mil) but then declined from Jun. 2023 ($178.76 Mil) to Dec. 2023 ($-17.49 Mil).

Mereo BioPharma Group's annual Accumulated other comprehensive income (loss) declined from Dec. 2021 ($184.76 Mil) to Dec. 2022 ($-21.69 Mil) but then increased from Dec. 2022 ($-21.69 Mil) to Dec. 2023 ($-17.49 Mil).

Mereo BioPharma Group Accumulated other comprehensive income (loss) Historical Data

The historical data trend for Mereo BioPharma Group's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mereo BioPharma Group Accumulated other comprehensive income (loss) Chart

Mereo BioPharma Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accumulated other comprehensive income (loss)
Get a 7-Day Free Trial Premium Member Only 86.08 181.56 184.76 -21.69 -17.49

Mereo BioPharma Group Semi-Annual Data
Jun15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Accumulated other comprehensive income (loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 184.76 166.84 -21.69 178.76 -17.49

Mereo BioPharma Group Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

Mereo BioPharma Group Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of Mereo BioPharma Group's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Mereo BioPharma Group (Mereo BioPharma Group) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mereo BioPharma Group PLC (NAS:MREO) » Definitions » Accumulated other comprehensive income (loss)
Comparable Companies
XTER:HPHA XTER:BNN XTER:MDG1 XTER:T5O XTER:FYB XTER:MOR OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX BGNE SZSE:300122 ALNY OCSE:GMAB
Traded in Other Exchanges
MAH0:Germany MAH0:Germany
Address
One Cavendish Place, 4th Floor, London, GBR, W1G 0QF
Website
https://www.mereobiopharma.com
Mereo BioPharma Group PLC is a multi-asset, clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its oncology product candidate is etigilimab, for patients with solid tumors. Some of the other products in the pipeline are setrusumab, alvelestat, leflutrozole, navicixizumab, and acumapimod.